Last reviewed · How we verify
HMI-115-120mg-Q4W
At a glance
| Generic name | HMI-115-120mg-Q4W |
|---|---|
| Sponsor | Hope Medicine (Nanjing) Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HMI-115-120mg-Q4W CI brief — competitive landscape report
- HMI-115-120mg-Q4W updates RSS · CI watch RSS
- Hope Medicine (Nanjing) Co., Ltd portfolio CI